Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
VERAXA Biotech (NASDAQ: VRXA) advances its VXA-222 cancer program beyond discovery, filing first patents on its BiTAC platforms while building a diversified oncology pipeline of bispecific antibodies and ADCs. #Oncology #Biotech
2026-08-27T11:13:02.864Z